CFDE Data Portal | Search LOC105370791

	Label	Description
	LOC105370791 Gene (Entity type)	ENSG00000260926 - uncharacterized LOC105370791
	GSE111247 temozolomide LN-308 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 14 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE112202 digoxin 5 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 11 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 11 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 6 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GTEx Brain 20-29 vs 60-69 Up Gene Set (Entity type)	A Gene Set from GTEx
	GSE99503 GSK3 TUNAR inhibition B cell 2 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS

LOC105370791

ENSG00000260926 - uncharacterized LOC105370791

GSE111247 temozolomide LN-308 0 v 6 human up

A Gene Set from LINCS

GSE48812 sulforaphane 2 v 5 human up

A Gene Set from LINCS

GSE111247 temozolomide LN-308 14 v 6 human up

A Gene Set from LINCS

GSE112202 digoxin 5 v 2 human dn

A Gene Set from LINCS

GSE48812 sulforaphane 11 v 5 human dn

A Gene Set from LINCS

GSE111247 temozolomide LN-308 11 v 6 human up

A Gene Set from LINCS

GSE195568 palbociclib 6 v 0 human dn

A Gene Set from LINCS

GTEx Brain 20-29 vs 60-69 Up

A Gene Set from GTEx

GSE99503 GSK3 TUNAR inhibition B cell 2 v 3 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.